Board of Directors

Henry A. Plain, Jr.

Chairman of the Board

Henry A. Plain, Jr. has served on XTENT's board of directors since June 2002 and as Chairman of XTENT's board of directors since October 2004. Mr. Plain also served as XTENT's President and Chief Executive Officer from June 2002 to October 2004. Mr. Plain joined Morgenthaler Ventures as Partner in September 2007 and has been the Vice Chairman of the board of directors of The Foundry since July 2000. From February 1993 to November 1999, Mr. Plain was the President and Chief Executive Officer and a member of the board of directors of Perclose and directed Perclose through an initial public offering, a secondary offering and an acquisition by Abbott Laboratories in November 1999. Following the acquisition of Perclose by Abbott Laboratories, Mr. Plain served as the President of Perclose and Vice President of Hospital Products Division at Abbott Laboratories until May 2000. Mr. Plain also serves on the boards of several privately-held medical device companies. Mr. Plain holds a B.S. in Business Administration from the University of Missouri, Columbia.

Robert C. Bellas, Jr.

Director

Robert C. Bellas, Jr. has served on XTENT's board of directors since July 2002. Mr. Bellas has been a General Partner at Morgenthaler Ventures, a venture capital firm, since January 1984. Mr. Bellas also serves on the boards of IPC- The Hospitalist Company, and on the boards of several privately-held healthcare and information technology companies. Mr. Bellas holds a B.S. in Engineering, Math, Chemistry and Physics from the U.S. Naval Academy and an M.B.A. from Stanford University.

Michael A. Carusi

Director

Michael A. Carusi has served on XTENT's board of directors since May 2003. He has been a General Partner at Advanced Technology Ventures, a venture capital firm, since October 1998. Mr. Carusi also serves on the board of TranS1, Inc., a public medical device company, and on the boards of several privately-held life sciences and medical device companies. Mr. Carusi holds a B.S. in Mechanical Engineering from Lehigh University and an M.B.A. from Dartmouth College.

Gregory D. Casciaro

Director

Gregory D. Casciaro has served as XTENT's President, Chief Executive Officer and a member of XTENT's board of directors since September 2004. From February 2000 to August 2003, Mr. Casciaro was the President and Chief Executive Officer and a director of Orquest, a medical technology company acquired by Johnson & Johnson. Mr. Casciaro currently serves on the board of one privately-held company. His career includes positions with General Surgical Innovations (acquired by United States Surgical) and vice president of sales for Guidant Corporation. Mr. Casciaro holds a B.A. in Business Administration from Marquette University.

Michael L. Eagle

Director

Michael L. Eagle has served on XTENT's board of directors since August 2007. Mr. Eagle has over 30 years of experience in manufacturing and general management. Prior to serving at Eli Lilly and Company for eight years as Vice President of Manufacturing, Eagle was Chief Executive Officer of IVAC Corporation, and served as the Senior Vice President of Operations of the Medical Devices and Diagnostics Division of Eli Lilly, which became Guidant Corporation after its 1995 spinoff from Eli Lilly. Mr. Eagle is Chairman of the Board of Directors of Favrille, Inc., and also serves on the board of Somaxon Pharmaceutical, Micrus Endovascular and a privately-held manufacturing corporation. Mr. Eagle received his B.S. Degree in Mechanical Engineering from Kettering University and his M.B.A. from the Krannert School of Management at Purdue University.

Robert E. Flaherty

Director

Robert E. Flaherty has served on XTENT’s board of directors since January 2007. Mr. Flaherty served as Chairman, President and Chief Executive Officer of Athena Diagnostics, a commercial laboratory company, since 1992. Athena Diagnostics was acquired by Thermo Fisher Scientific in November 2006. Prior to Athena Diagnostics, Mr. Flaherty was employed by Becton, Dickinson and Company, a medical technology company, and held various positions including President of the Becton Dickinson Division. Mr. Flaherty currently serves on the board of directors of AngioDynamics and is the Chairman of its compensation committee. He also serves on the board of one privately-held corporation. Mr. Flaherty holds a B.S. in Industrial Engineering from Lehigh University and an M.B.A. from Harvard University.

Edward W. Unkart

Director

Edward W. Unkart was appointed to XTENT's board of directors in August 2006. Since January 2005, Mr. Unkart has served as Vice President of Finance and Administration and Chief Financial Officer of SurgRx, a manufacturer of medical devices used in surgery. From June 2004 to December 2004, Mr. Unkart was an independent consultant. From May 2001 to May 2004, Mr. Unkart served as Vice President of Finance and Administration and Chief Financial Officer of Novacept, a manufacturer of medical devices for women's healthcare, which was acquired by Cytyc Corporation in March 2004. Mr. Unkart currently serves on the board of directors of VNUS Medical Technologies, a publicly-traded medical device company, and is the chairperson of its audit committee. Mr. Unkart also serves on the board of directors of a privately-held medical device company. Mr. Unkart is a Certified Public Accountant and holds a B.S. in Statistics and an M.B.A. from Stanford University.

Allan R. Will

Director

Allan R. Will has served on XTENT's board of directors since July 2002 and as Chairman of XTENT's board of directors from July 2002 to October 2004. Mr. Will has been a Managing Director of Split Rock Partners, a venture capital firm, since July 2004. From November 2002 to June 2004, Mr. Will was a General Partner at St. Paul Venture Capital, a venture capital firm. Mr. Will is the founder and Chairman of the board of directors of The Foundry and served as its Chief Executive Officer from 1998 until 2002. Mr. Will also served as the interim Chief Executive Officer of Concentric Medical from 2001 to 2002, as Chief Executive Officer of Evalve from 1999 to 2000, as the President and Chief Executive Officer of AneuRx from 1994 to 1997. Mr. Will also serves on the boards of several privately-held medical device companies. Mr. Will holds a B.S. in Zoology from the University of Maryland and an M.S. in Management from the Massachusetts Institute of Technology.